Physician profile
James S Evans
NPI 1396769543
$4,164.99
in general payments reported to CMS, 2019-2025
25 companies · $577 in 2025
The $577 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,020 · 2020: $249 · 2021: $669 · 2022: $606 · 2023: $607 · 2024: $436 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $829.86 | 2019-2025 | Yeztugo |
| Viiv Healthcare Company | $620.84 | 2019-2025 | Dovato, Cabenuva |
| Octapharma USA, INC. | $614.81 | 2021-2025 | Panzyga, Octagam Immune Globulin (Human), Cutaquig |
| Merck Sharp & Dohme LLC | $511.82 | 2019-2025 | Zerbaxa, Prevymis, Dificid |
| Abbvie INC. | $351.08 | 2020-2025 | |
| Cumberland Pharmaceuticals, INC. | $166.73 | 2019-2025 | Vibativ |
| Allergan, INC. | $153.59 | 2019 | |
| Astellas Pharma US INC | $126.94 | 2019-2025 | Cresemba |
| Melinta Therapeutics, LLC | $121.31 | 2019-2021 | |
| Janssen Biotech, INC. | $106.72 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $69.72 | 2019-2025 | Nuzyra |
| Insmed, INC. | $61.75 | 2023-2024 | Arikayce |
| Mayne Pharma Commercial LLC | $60.41 | 2019 | |
| Hospira, INC. | $59.00 | 2024-2025 | |
| Shionogi INC | $55.90 | 2021-2023 | Fetroja |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $49.02 | 2023 | |
| Emd Serono, INC. | $44.85 | 2023 | Serostim |
| Cipla USA INC. | $27.67 | 2020 | |
| Ferring Pharmaceuticals INC. | $21.82 | 2025 | Rebyota |
| Tetraphase Pharmaceuticals, INC. | $20.31 | 2020 | |
| Invivyd INC | $19.87 | 2025 | Pemgarda |
| Pfizer INC. | $19.67 | 2023 | |
| Vyera Pharmaceuticals, LLC | $18.98 | 2022 | |
| Theratechnologies INC. | $18.80 | 2020 | |
| Dynavax Technologies Corporation | $13.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.